ERCC1 Genotype Can Identify Good Prognosis in Nasopharyngeal Cancer

Share this content:
Excision repair cross-complementing group 1 genotype may identify favorable prognosis for subgroup of nasopharyngeal carcinoma.
Excision repair cross-complementing group 1 genotype may identify favorable prognosis for subgroup of nasopharyngeal carcinoma.

Excision repair cross-complementing group 1 (ERCC1) genotype for the single nucleotide polymorphism (SNP) cytosine-to-thymine substitution at codon 118 (C118T) interacts with post-radiotherapy plasma Epstein-Barr virus (EBV) DNA (pEBV) to identify favorable prognosis for a subgroup of patients with nasopharyngeal carcinoma (NPC), according to a study published in Cancer.

Edwin P. Hui, M.D., from The Chinese University of Hong Kong, and colleagues examined whether the ERCC1 genotype for the SNPs C118T and cytosine-to-adenine substitution at codon 8092 (C8092A) is prognostic in patients with NPC.

The authors evaluated the hypothesis using biomarker screening samples from a prospective, multicenter trial that used post-radiotherapy pEBV levels to screen high-risk NPC patients for adjuvant chemotherapy. ERCC1 SNPs were analyzed in 576 patients who underwent pEBV screening.

The researchers found that neither ERCC1 C118T nor C8092A genotype correlated with relapse-free survival (RFS) or overall survival (OS). In multivariate analyses, only post-radiotherapy pEBV status independently predicted RFS and OS.

A significant interaction was seen for ERCC1 C118T genotype and pEBV status (RFS, P = 0.0106; OS, P = 0.0067). In the pEBV-negative, but not pEBV-positive, population, ERCC1 C118T genotype correlated with both RFS and OS (hazard ratios, 1.67 and 2.31, respectively).

RELATED: Adding Chemotherapy to Radiotherapy Improves Nasopharyngeal Carcinoma Survival

"The ERCC1 C118T genotype may help to identify a favorable subgroup (approximately 7 percent) of pEBV-negative patients with NPC who have an excellent prognosis and can be spared the toxicities of further therapy," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Reference

  1. Hui EP, Ma BBY, Chan KCA, et al. Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma. Cancer. 2015. [online ahead of print]. DOI: 10.1002/cncr.29413.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters